Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.pSivida has reported total revenues of $360,000 for the third quarter ended 31March 2011, as compared to $515,000 for the same period in 2010.
Subscribe to our email newsletter
The company has posted a net loss of $2.69m for the third quarter 2011, or $0.13 loss per diluted share, compared to net loss of $2.71m, or $0.15 loss per diluted share, for the comparable period in 2010.
pSivida’s loss from operations was $3.14m, compared to $2.86m for the comparable period in 2010.
For the nine months ended 31 March 2011, the company has posted total revenues of $1.25m, as compared to $7.33m for the same period last year.
Net loss was $8.49m, or $0.45 loss per diluted share, compared to $4.32m, or $0.24 loss per diluted share, for the year ago period.
Loss from operations was $9.7m for the nine moths ended 31 March 2011, as compared to $3.08m for the same period prior year.
pSivida president and CEO Paul Ashton said they continue to make steady progress on other internal and collaborative projects and product development based on their proprietary drug delivery platforms continues to be a primary focus for the company.